Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8009 in Advanced Solid Tumours
NCT05405621Phase 1Unknown
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT8009 in solid tumor (8 cohorts), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Dose-limiting toxicity at 21 days. Status: unknown.
02
Drugs
BAT8009
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05405621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405621.